Insights into the mechanisms of serplulimab: a distinctive anti-PD-1 monoclonal antibody, in combination with a TIGIT or LAG3 inhibitor in preclinical tumor immunotherapy studies by Yizhou Zhang, Ruicheng Wei, Ge Song, Xinyi Yang, Mengli Zhang, Wei Liu, Aiying Xiong, Xuehan Zhang, Qianhao Li, Wan-Jen Yang, Chencheng Han, Rui Liu, Chen Hu, Qingyu Wang, Jun Zhu, Yongqiang Shan

Subjects: “…Anti-PD-1/PD-L1…”
Get full text

Discovery of novel biphenyl compounds bearing hydroxamic acid moiety as the first PD-L1/class I HDACs dual inhibitors by Dandan Yuan, Yali Gao, Lin Xia, Han Liu, Xingye Wu, Xueyan Ding, Yudan Huang, Changchun Deng, Jin Li, Wenqi Dai, Jieqing Liu, Junjie Ma

Subjects: “…PD-1/PD-L1…”
Get full text

Inosine enhances the efficacy of immune‐checkpoint inhibitors in advanced solid tumors: A randomized, controlled, Phase 2 study by Haiqing Zhao, Wei Zhang, Yuting Lu, Yin Dong, Zhihao He, Hongchao Zhen, Qin Li

Subjects: Get full text

Extraction, GC-MS analysis, cytotoxic, anti-inflammatory and anticancer potential of Cannabis sativa female flower; in vitro, in vivo and in silico by Waqas Safir, Arif Malik, Arif Malik, Haleema Saadia, Ayesha Zahid, Jinyao Li

Subjects: Get full text

Periodontitis promotes tumor growth and immune evasion via PD-1/PD-L1 by Suli Wang, Fujiao Nie, Qiuyue Yin, Haoyang Tian, Pizhang Gong, Jinhong Ju, Jiayi Liu, Pishan Yang, Chengzhe Yang

Subjects: Get full text

Progression patterns in patients with advanced hepatocellular carcinoma treated with local therapy, targeted drugs, and PD-1/PD-L1 inhibitors by Yanan Zhao, Di Wu, Quanjun Yao, Hang Yuan, Hongtao Hu, Hailiang Li

Subjects: Get full text

Comparison of the Efficacy and Safety of PD‐1/PD‐L1 Inhibitors in the Treatment of Small Cell Lung Cancer by Qichen Zhang, Xiaojuan Han, Jiayi Liu, Hui Qiao

Subjects: Get full text

Lutetium-177 labeled iPD-L1 as a novel immunomodulator for cancer-targeted radiotherapy by Myrna Luna-Gutiérrez, Erika Azorín-Vega, Rigoberto Oros-Pantoja, Blanca Ocampo-García, Pedro Cruz-Nova, Nallely Jiménez-Mancilla, Gerardo Bravo-Villegas, Clara Santos-Cuevas, Laura Meléndez-Alafort, Guillermina Ferro-Flores

Subjects: Get full text

Effectiveness and safety of pembrolizumab, nivolumab, and atezolizumab as adjuvant therapy for high-risk muscle-invasive urothelial carcinoma: an indirect comparison by Wei Chen, Wei Chen, Soichiro Yoshida, Noriyoshi Miura, Shohei Fukuda, Hiroshi Fukushima, Yuma Waseda, Hajime Tanaka, Yasuhisa Fujii

Subjects: Get full text

Immune-related adverse events with PD-1/PD-L1 inhibitors: insights from a real-world cohort of 2523 patients by Ting Yan, Minghui Long, Chaoyi Liu, Jiwen Zhang, Jiwen Zhang, Xingyu Wei, Xingyu Wei, Fei Li, Fei Li, Dehua Liao

Subjects: “…PD-1/PD-L1 inhibitors…”
Get full text

Targeting HGF/c-MET signaling to regulate the tumor microenvironment: Implications for counteracting tumor immune evasion by Yang Xia, Chunye Huang, Min Zhong, Hongguang Zhong, Ruiwen Ruan, Jianping Xiong, Yangyang Yao, Jing Zhou, Jun Deng

Subjects: Get full text

Illuminating the impact of CD38-induced adenosine formation in B-cell lymphoma by Shams ElDoha Galal ElDin Zaiema, Heba Mohamed Saber Hafez, Diaa El-Din Moussa Sherif Abou El-Ela, Rawda Ahmed Alaaeldin Ahmed Mohamed Saad

Subjects: Get full text

Sigma1 inhibitor suppression of adaptive immune resistance mechanisms mediated by cancer cell derived extracellular vesicles by Paola A. Castagnino, Derick A. Haas, Luca Musante, Nathalia A. Tancler, Bach V. Tran, Rhonda Kean, Alexandra R. Steck, Luis A. Martinez, Elahe A. Mostaghel, D. Craig Hooper, Felix J. Kim

Subjects: “…programmed death ligand 1 (PD-L1)…”
Get full text